| An enolase inhibitor for the targeted treatment of ENO1-deleted cancers YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ... Nature metabolism 2 (12), 1413-1426, 2020 | 48 | 2020 |
| KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells KK Mahadevan, KM McAndrews, VS LeBleu, S Yang, H Lyu, B Li, ... Cancer Cell 41 (9), 1606-1620. e8, 2023 | 33 | 2023 |
| Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine Y Barekatain, JJ Ackroyd, VC Yan, S Khadka, L Wang, KC Chen, ... Nature communications 12 (1), 4228, 2021 | 26 | 2021 |
| Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma S Khadka, K Arthur, Y Barekatain, E Behr, M Washington, J Ackroyd, ... Cancer & Metabolism 9 (1), 27, 2021 | 15 | 2021 |
| Structure-guided microbial targeting of antistaphylococcal prodrugs JJ Miller, IT Shah, J Hatten, Y Barekatain, EA Mueller, AM Moustafa, ... Elife 10, e66657, 2021 | 13 | 2021 |
| Targeting host glycolysis as a strategy for antimalarial development AJ Jezewski, YH Lin, JA Reisz, R Culp-Hill, Y Barekatain, VC Yan, ... Frontiers in Cellular and Infection Microbiology 11, 730413, 2021 | 11 | 2021 |
| Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB MO Mikati, JJ Miller, DM Osbourn, Y Barekatain, N Ghebremichael, ... ACS infectious diseases 6 (11), 3064-3075, 2020 | 9 | 2020 |
| Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination … KK Mahadevan, KM McAndrews, VS LeBleu, S Yang, H Lyu, B Li, ... bioRxiv, 2023.02. 15.528757, 2023 | 7 | 2023 |
| Quantification of Phosphonate Drugs by 1H–31P HSQC Shows That Rats Are Better Models of Primate Drug Exposure than Mice Y Barekatain, S Khadka, K Harris, J Delacerda, VC Yan, KC Chen, ... Analytical Chemistry 94 (28), 10045-10053, 2022 | 6 | 2022 |
| Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers VC Yan, CD Pham, ES Ballato, KL Yang, K Arthur, S Khadka, ... Journal of Medicinal Chemistry 65 (20), 13813-13832, 2022 | 3 | 2022 |
| Robust detection of oncometabolic aberrations by 1H–13C heteronuclear single quantum correlation in intact biological specimens Y Barekatain, VC Yan, K Arthur, JJ Ackroyd, S Khadka, J De Groot, ... Communications Biology 3 (1), 328, 2020 | 3 | 2020 |
| Re-evaluating the mechanism of histone lactylation S Khadka, Y Barekatain, F Muller OSF, 2020 | 3 | 2020 |
| Comparative pharmacology of a bis-pivaloyloxymethyl phosphonate prodrug inhibitor of enolase after oral and parenteral administration VC Yan, Y Barekatain, YH Lin, N Satani, N Hammoudi, K Arthur, ... ACS Pharmacology & Translational Science 6 (2), 245-252, 2023 | 1 | 2023 |
| Methylthioadenosine is Not Dramatically Elevated in MTAP-Homozygous Deleted Primary Glioblastomas Y Barekatain, VC Yan, JJ Ackroyd, AH Poral, T Tran, DK Georgiou, ... bioRxiv, 769885, 2019 | 1 | 2019 |
| Abstract B092: CDK8 and CXCL2 remodel the tumor microenvironment to contribute to KRASG12D small molecule inhibition resistance in pancreatic ductal … KM McAndrews, KK Mahadevan, B Li, AM Sockwell, SJ Morse, PJ Kelly, ... Cancer Research 84 (2_Supplement), B092-B092, 2024 | | 2024 |
| CDK8 and CXCL2 remodel the tumor microenvironment to contribute to KRASG12D small molecule inhibition resistance in pancreatic ductal adenocarcinoma KM McAndrews, KK Mahadevan, B Li, AM Sockwell, SJ Morse, PJ Kelly, ... CANCER RESEARCH 84 (2), 2024 | | 2024 |
| Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism S Khadka, YH Lin, J Ackroyd, YA Chen, Y Sheng, W Qian, S Guo, Y Chen, ... bioRxiv, 2023 | | 2023 |
| PRMT5 inhibition synergizes with a natural small molecule compound to kill MTAP-deleted cells and suppress tumor growth Y Barekatain, K LaBella, H Sugimoto, K Harris, S Khadka, F Muller, ... Cancer Research 83 (7_Supplement), 1073-1073, 2023 | | 2023 |
| Therapeutic Potential Of Prmt5 And Mat2A As Synthetic Lethal Targets In Mtap-Deficient Gbm Tumors Y Barekatain | | 2023 |
| Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine Y Barekatain, J Ackroyd, V Yan, S Khadka, KC Chen, R Kalluri, J de Groot, ... Cancer Research 82 (12_Supplement), 2395-2395, 2022 | | 2022 |
